Skip to content

AngioDynamics

US · ANGO #3631 by market cap
10.81 +0.05 +0.46%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:01

Valuation each multiple against its own 5-year range

P/B ratio 3.04 Expensive vs history 92nd percentile
5-year average 1.83 · #30 of 51 in Medical Instruments & Supplies
P/E ratio -15.03 In line with history 47th percentile
5-year average -10.39 · forward -19.90
P/S ratio 1.53 In line with history 59th percentile
5-year average 1.56 · forward 1.46 · #12 of 51 in Medical Instruments & Supplies

Vs. peers Medical Instruments & Supplies

Company Market cap P/E (TTM) P/B Div yield
AngioDynamics (ANGO) 454.61M -13.68 2.77 0.00%
Intuitive Surgical (ISRG) 138.33B 48.25 8.65 0.00%
Becton Dickinson & Co (BDX) 57.96B 52.02 2.35 1.97%
Alcon (ALC) 35.92B 54.24 1.64 0.48%
ResMed (RMD) 33.14B 21.46 5.57 1.04%
Medline (MDLN) 32.55B 57.52 2.76 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value11.83 Economic moatNone UncertaintyHigh

Trading 9.4% below Morningstar's fair value estimate.

Fair value

AngioDynamics Inc earns a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a price consistent with our quantitative fair value estimate, which has a high uncertainty rating.

The company's lack of profitability decreases our estimated valuation. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. For example, the firm's earnings yield of -0.8% lies in the bottom 30% compared with peers globally. The earnings generated by the company relative to its share price is concerning, which contributes to our balanced fair value estimate.

The company's valuation metrics are an additional cause for concern. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's book value yield of 32.9%, for example, sits in the bottom 30% compared with global peers. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which further promotes our neutral price/fair value ratio.

Economic moat

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 20:01:15 · For reference only, not investment advice and not tailored to your situation.

AngioDynamics discussion 0 comments

Add a comment